Mesoblast Limited's (ASX:MSB) Allogeneic, "Off-The-Shelf", Stem Cells Are Safe And Effective For Cervical Spine Fusion

Published: Aug 21, 2008

Melbourne, Aug 21, 2008 (ABN Newswire) - Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its allogeneic, or "off-the-shelf", cell therapy product was safe and highly effective in preclinical trials for interbody fusion of the cervical spine in the neck.

Back to news